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Neurobiology of Disease
Early Stage Drug Treatment That Normalizes
Proinflammatory Cytokine Production Attenuates Synaptic
Dysfunction in a Mouse Model That Exhibits Age-Dependent
Progression of Alzheimer’s Disease-Related Pathology
AdamD. Bachstetter,1 Christopher M. Norris,1,2 Pradoldej Sompol,1DonnaM.Wilcock,1,3Danielle Goulding,1
Janna H. Neltner,1,4Daret St. Clair,1,5,7D. MartinWatterson,8 and Linda J. Van Eldik1,6
1Sanders-Brown Center on Aging, Departments of 2Molecular and Biomedical Pharmacology, 3Physiology, 4Pathology, 5Toxicology, and 6Anatomy and
Neurobiology, and 7Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, and 8Department of Molecular Pharmacology and
Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611
Overproduction of proinflammatory cytokines in the CNS has been implicated as a key contributor to pathophysiology progression in
Alzheimer’s disease (AD), and extensive studies with animal models have shown that selective suppression of excessive glial proinflam-
matory cytokines can improve neurologic outcomes. The prior art, therefore, raises the logical postulation that intervention with drugs
targeting dysregulated glial proinflammatory cytokine production might be effective disease-modifying therapeutics if used in the
appropriate biological time window. To test the hypothesis that early stage intervention with such drugs might be therapeutically
beneficial, we examined the impact of intervention with MW01-2-151SRM (MW-151), an experimental therapeutic that selectively
attenuates proinflammatory cytokine production at low doses. MW-151 was tested in an APP/PS1 knock-in mouse model that exhibits
increases inAD-relevantpathologyprogressionwith age, including increases inproinflammatory cytokine levels.Drugwas administered
during two distinct but overlapping therapeutic time windows of early stage pathology development. MW-151 treatment attenuated the
increase in microglial and astrocyte activation and proinflammatory cytokine production in the cortex and yielded improvement in
neurologic outcomes, such as protection against synaptic protein loss and synaptic plasticity impairment. The results also demonstrate
that the therapeutic time window is an important consideration in efficacy studies of drugs that modulate glia biological responses
involved in pathology progression and suggest that such paradigms should be considered in the development of new therapeutic regi-
mens that seek to delay the onset or slow the progression of AD.
Introduction
Alzheimer’s disease (AD) and related neurodegenerative disorders
have an unmet need for therapies that alter disease progression. Ev-
idence suggests that disease progression involves uncontrolled glial
activation and neuroinflammation that contribute to neuronal/syn-
aptic dysfunction,which in turn drives a vicious cycle of further glial
activation and neuronal damage (Mrak and Griffin, 2005). Dissect-
ing this cycle to find points of potential therapeutic intervention is
compounded by the complexity of this multifactorial disease, the
multiple roles of glia in homeostasis andhost defense, and the diver-
sity of inflammatory and immune responsemechanisms (Nelson et
al., 2009, 2011; Cameron and Landreth, 2010; Huang and Mucke,
2012;Wyss-Coray and Rogers, 2012).
The diverse array of physiological functions that glia perform,
which are context dependent, complicates the interpretation of
experimental investigations and clinical observations related to
AD pathology. For example, astrocytes and microglia interact
with neurons at the synapse to modulate synaptic function and
plasticity (Eroglu and Barres, 2010; Tremblay et al., 2011) and are
also vital for host defense mechanisms and response to stress
(Ransohoff and Perry, 2009). Therefore, health and homeostasis,
disease progression and susceptibility, and therapeutic interven-
tions involve a delicate balance in which glial responses must be
modulated within a dynamic range.
Related to disease progression, extended overproduction of
proinflammatory cytokines such as IL-1 can be particularly det-
rimental to neuronal function (Shaftel et al., 2008; Hein et al.,
2010; Kitazawa et al., 2011). The potential for amelioration of
cytokine-induced neuronal dysfunction through therapeutic in-
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tervention was shown by Hu et al. (2007) with the development
of a small molecule experimental therapeutic, MW01-2-151SRM
(here termed MW-151). MW-151 is a selective suppressor of 
amyloid (A)-induced glia proinflammatory cytokine produc-
tion, with resultant attenuation of the cytokine-induced loss of
synaptic marker proteins (e.g., synaptophysin and PSD-95) and
cognitive deficits (Hu et al., 2007). A major unmet challenge in
the field, however, is the question of a therapeutic timewindow in
progressive neurological disorders like AD. The therapeutic time
window is a component of drug dosing, a fundamental aspect of
the pharmacological basis of drug action, and is linked to the
clinical principle of pathology progression. For example, an op-
timal time window for therapeutic intervention is generally dur-
ing a peak activity change in the targeted pathway involved in
pathology progression.
To address the issue ofwhether glial activation and proinflam-
matory cytokine increases might be an early stage pathology
progression feature that could be modulated by drugs such as
MW-151 with resultant improvement in neurologic endpoints,
we examined an APP/PS1 humanized knock-in mouse model
that exhibits age-dependent AD pathology progression. We
found that proinflammatory cytokines begin to increase early in
the pathology progression and that repeat dose intervention with
MW-151 starting during this period resulted in significantly im-
proved outcomes. While improvements were also seen with later
short-term intervention, the earlier and more prolonged inter-
vention yielded more robust effects. Neither dosing paradigm
had a detectable effect on amyloid plaque load or A levels. The
results indicate that selective inhibition of increasing proinflam-
matory cytokine production early in disease progression is ben-
eficial at maintaining synaptic function.
Materials andMethods
Synthesis of MW-151.MW01-2-151SRM [2-(4-(4-methyl-6-phenylpyridazin-
3-yl)piperazin-1-yl)pyrimidine] was synthesized and characterized as reported
previously (Hu et al., 2007). The active pharmaceutical used for biological
studies was the dihydrochloride hydrate formof thewater-soluble, acidic
drug. Low doses per administration were employed as noted and are
similar to those used previously for efficacy in diverse animal models of
CNS diseases that involve excessive proinflammatory cytokine produc-
tion as part of the pathology progression mechanism, including a model
of early AD (Hu et al., 2007), TBI (Lloyd et al., 2008; Chrzaszcz et al.,
2010), multiple sclerosis (Karpus et al., 2008), and seizures (Somera-
Molina et al., 2007, 2009) at low doses similar to those used in this study.
APP/PS1 knock-in mice. The AD mouse model used is the APPNLh/NLh 
PS1P264L/P264L mutant mice originally developed at Cephalon (Flood et
al., 2002). This double mutant mouse was generated by using gene tar-
geting knock-in (KI) technology to introduce the Swedish FAD K670N/
M671L mutations and humanize the mouse A sequence (NLh) and to
introduce the proline to leucine (P264L) mutation in the mouse PS-1
gene (Reaume et al., 1996; Siman et al., 2000). Expression of both genes is
driven by the endogenous promoters, and thus this model shows AD
pathology without APP or PS1 overproduction. The APP/PS1 KI mice
were maintained on a CD-1/129 background, and wild-type (WT) mice
were obtained from heterozygous APP/PS1 matings andmaintained as a
separate line for20 generations of inbred mice used as controls. Mice
were monitored for maintenance of the appropriate genotypes by PCR
analysis of tail snip DNA (Anantharaman et al., 2006). Mice were main-
tained under 12 h light/dark cycles and provided food and water ad
libitum. All animal protocols followed the principles of animal care and
experimentation in theGuide for the Care and Use of Laboratory Animals,
and were approved by the Institutional Animal Care andUse Committee
of the University of Kentucky (Lexington, KY).
Treatment of mice.MW-151was dissolved in 0.9% sterile NaCl (saline;
HospiraNDC0409-4888-10). Two experimental paradigmswere used to
test MW-151 efficacy in the APP/PS1 mice. In the extended administra-
tion prevention study (chronic intervention paradigm), MW-151 was
administered at a low dose (2.5 mg/kg) by intraperitoneal (i.p.) injection
three times per week (Monday, Wednesday, Friday), beginning when
mice were 6 months old and ending at 11 months. In the short-term
treatment study (acute intervention paradigm), MW-151 (2.5 mg/kg)
was administered i.p. to 11-month-old mice once daily for 1 week. Con-
trols included APP/PS1 KI or WT mice administered vehicle control
(saline). To conserve on animal numbers, WT mice were not adminis-
tered MW-151. Each experimental group (WT plus vehicle, APP/PS1 KI
plus vehicle, APP/PS1 KI plus MW-151) started with 12 mice of either
sex, and the numbers ofmales and females in each groupwerematched as
closely as possible.
Euthanasia and brain tissue harvesting.Mice were euthanized with an
overdose of sodium pentobarbital and transcardially perfused with ice-
cold PBS for 5 min. The brains were rapidly removed and bisected along
the sagittal plane. The right hemisphere was further dissected and flash
frozen in liquid nitrogen and stored at80°C for subsequent biochem-
ical evaluation. The left hemisphere was immersion fixed in 4% parafor-
maldehyde overnight before cryoprotection in a 30% sucrose/PBS
solution.
Biochemical endpoint analyses. Neocortical tissue was homogenized
using an Omni TH homogenizer in a lysis buffer (1:10 w/v) containing
PBS, 1mM EDTA, and protease inhibitors (1mM PMSF, 1g/ml leupep-
tin). Extracts were centrifuged at 12,000  g for 20 min at 4°C in a
Beckman Microfuge 18, and supernatants were used as the PBS soluble
fraction. Pellets were suspended and rehomogenized in a detergent-
containing lysis buffer (tissue protein extraction reagent with Halt Pro-
tease and Phosphatase Inhibitor Cocktail; Thermo Scientific) at the same
volume used for the first homogenization. Extracts were centrifuged at
12,000 g for 20 min at 4°C, and supernatants were used for measure-
ment of synaptic proteins in the detergent-soluble fraction. The pellet
was then resuspended and rehomogenized in 70% formic acid (FA). The
FA homogenate was centrifuged at 1,000,000 g at 4°C for 60 min. The
supernatant was neutralized 1:20with 1MTris (pH11) and used as the FA
soluble fraction. Levels of A40 andA42weremeasured by ELISA assay
using kits fromMeso Scale Discovery (MSD) according to the manufac-
turer’s instructions. Levels of cytokines (IL-1 and IL-10)weremeasured
by ELISA assay using kits from MSD according to the manufacturer’s
instructions with minor modifications. Briefly, 50 l of the PBS soluble
fraction was loaded per well of the MSD plate (100–200 g of protein).
The sample was incubated in the plate overnight at 4°C. All incubation
steps were done using an Eppendorf MixMate at 1000 rpm. Cytokine
levels were normalized to the total amount of protein in the sample
loaded as determined by BCA Protein Assay (Thermo Scientific). The
detection limits of the MSD assays are 1.5 pg/ml for IL-1 and 42 pg/ml
for IL-10 in serum/plasma.
Levels of synaptic proteins were measured by Western blots as de-
scribed previously (Xing et al., 2011). Briefly, 1 g of the detergent-
solubilized fraction was prepared in SDS buffer (LI-COR Biosciences ).
The sample was separated on a 10% NuPAGE Novex Bis-Tris Midi Gel
(Invitrogen). Proteins were transferred to nitrocellulose membrane us-
ing a dry blotting system (iBlot, Invitrogen). Blots were probed using
reagents and manufacturer recommendations for Odyssey Infrared Im-
aging System (LI-COR Biosciences). Blots were probed for the following
primary antibodies: rabbit anti-PSD95 (1:2000, Cell Signaling Technol-
ogy, catalog no. 3450); mouse anti-synaptophysin (clone SY38) (1:
30,000, Millipore, catalog no. MAB5258); rabbit anti-syntaxin 1 (1:
100,000, Millipore, catalog no. ab5820); mouse anti-SNAP 25 (clone 20)
(1:10,000, BD Biosciences, catalog no. 610366). Rabbit anti-GAPDH
(clone 14C10) (1:10,000, Cell Signaling Technology, catalog no. 2118)
was used as a loading control. Blots were visualized and analyzed on the
Odyssey Infrared Imaging System (LI-COR Biosciences), and integrated
intensity values were used in statistics.
For gene expression, dissected neocortical tissues stored at 80°C
were used for RNA isolation using RNeasy mini-columns (Qiagen, cata-
log no. 74104) with on-column DNase treatment (Qiagen, catalog no.
79254) according to the manufacturer’s protocol. RNA quantity and
quality were determined usingA260/A280 readings byNanoDrop (Thermo Sci-
entific).Reverse transcription (RT)wasdone following themanufacturer’s pro-
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tocol using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, catalog no. 4368814). A no template and a no RT control were
conducted to control for contamination. Real-time PCR was performed using
the TaqMan Gene Expression Assay Kit (Applied Biosystems, catalog no.
4444964) according to the manufacturer’s instructions on a ViiA 7 Real-Time
PCRSystem(AppliedBiosystems).ThefollowingTaqManprobes(AppliedBio-
systems) were used: GFAP (Mm00546086_m1), S100B (Mm00485897_m1),
vimentin (Mm01333430_m1), Actb (Mm00607939_s1), and IL-1
(Mm00434228_m1)(seeTable1).Relativegeneexpressionwascalculatedbythe
2CTmethod.
Immunohistochemical staining. Coronal sections (30 m) of the left
hemisphere were made using a sliding microtome and a freezing stage
and stored in cryoprotectant at 20°C. Staining procedures were con-
ducted on free-floating sections using every twelfth section of the entire
left cerebral cortex. Primary and secondary antibodieswere diluted in 3%
normal goat serum (NGS) (LAMPIRE Biological Laboratories, catalog
no. 7332500) with 0.2% Triton X-100. Amyloid plaque burden was de-
tected by rabbit polyclonal anti-A N-terminal antibody (1:10,000, In-
vitrogen, catalog no. 44338100). Sections were pretreated with 70%
formic acid and endogenous peroxidase activity was quenched with 3%
H2O2 in methanol, before the tissue blocking in 10% NGS with 0.2%
Triton X-100. The biotinylated secondary antibody (1:500, Jackson Im-
munoResearch Laboratories, catalog no. 111-065-144) was amplified us-
ing avidin-biotin substrate (ABC solution, Vector Laboratories catalog
no. PK-6100) followed by color development in 3,3-diaminobenzidine
tetra-hydrochloride (DAB; Sigma, catalog no. D5637). Glial activation
was detected with the following antibodies: rabbit anti-GFAP (1:10,000
Dako, catalog no. Z0334) for astrocytes and rabbit anti-IBA1 (1:10,000,
Wako, catalog no. 019-19741) for microglia. Endogenous peroxidase
activity was quenched with 3% H2O2 in methanol, followed by blocking
in 10% NGS with 0.2% Triton X-100. The horseradish peroxidase sec-
ondary antibodies (1:500, Jackson ImmunoResearch Laboratories, cata-
log no. 111-035-003) were visualized with DAB.
Quantitative image analysis of immunohistochemical stains.The Aperio
ScanScope XT digital slide scanner was used to image the entire stained
slide at 20 magnification to create a single high-resolution digital im-
age. The neocortex and hippocampus were outlined using the Aperio
ImageScope software. The Aperio-positive pixel count algorithm (ver-
sion 9) was used to quantify the amount of specific staining in the region.
The number of positive pixels was normalized to the number of total
pixels (positive and negative) to account for variations in the size of the
region sampled. The Aperio nuclear algorithm (version 9) was used to
quantify the number of cells or the number and size of A plaques in the
outlined region. To quantify the number of plaques as a function of size,
a threshold was set in the nuclear algorithm so only plaques that were
contained in the size binwould be quantified. Color and intensity thresh-
olds were established to detect the immunostaining as positive pixels and
background staining as negative pixels. Once conditionswere established
for an immunohistochemical stain, the entire batch of slides was ana-
lyzed with the same parameters. The resulting color markup of the anal-
ysis was confirmed for each slide. All quantifications were done by a
blinded observer.
Slice electrophysiology. Methods for preparing acute brain slices for
assessment of CA1 synaptic function and plasticity were similar to our
previous methods (Norris and Scheff, 2009; Mathis et al., 2011). Briefly,
12-month-old WT and APP/PS1 KI mice were decapitated under CO2
anesthesia, and brains were rapidly removed and stored in ice-cold arti-
ficial cerebrospinal fluid (ACSF) containing: 124 mM NaCl, 2 mM KCl,
1.25 mM KH2PO4, 2 mM MgSO4, 26 mM NaHCO3, 10 mM dextrose,
saturatedwith 95%O2 and 5%CO2. Cerebral hemispheres were blocked,
mounted, and sectioned (400 m) in ice-cold Ca2-free ACSF with a
vibrating microtome (Leica Biosystems). Slices were then stored on nets
in a humidified interface holding chamber and bathed in CaCl2 (2 mM)-
containing ACSF (32°C) with saline vehicle or 30 M MW-151. After a
1.5–2 h incubation period, slices were transferred to a modified RC-22
chamber (Warner Instruments) affixed to the stage of a Nikon E600
microscope (Nikon Instruments) and perfused (1–2 ml/min) with oxy-
genated CaCl2 (2mM)-containing ACSF (32°C). Synaptic responses were
evoked by electrical stimulation of CA3 Schaffer collaterals and recorded
in CA1 stratum radiatum as described previously (Norris and Scheff,
2009; Mathis et al. 2011). To generate synaptic strength curves, EPSP
amplitudes were measured at nine stimulus intensity levels (30, 50, 100,
150, 200, 250, 300, 400, and 500 mA) and plotted against corresponding
fiber volley (FV) amplitudes. For some slices, stimulus intensity was reset
after the synaptic strength curve to evoke a 1 mV EPSP every 30 s for at
least 20 min before the delivery of two 1 s duration trains of 100 Hz
stimulation (10 s intertrain interval) for induction of long term potenti-
ation (LTP). Synaptic responses were then collected for an additional 60
min. All electrophysiological recordings were conducted and analyzed by
personnel who were blind to genotype and drug treatment conditions.
Statistics. Statistical analysis was conducted using GraphPad prism
software version 5 (GraphPad Software). Values are expressed asmean
SEM. Groups of two were compared by unpaired t test. Groups of three
or more were compared by one-way ANOVA, followed by the Bonfer-
roni Multiple Comparison Test. Significance was defined as p  0.05.
Synaptic strength curves were fit with a three parameter (i.e., max EPSP
amplitude, half-maximal FV amplitude, and curve slope) sigmoidal
function and compared across treatment groups usingZ tests (Z values
2 were considered statistically significant). For each slice, LTP ampli-
tudes were averaged 50–60 min after delivery of 100 Hz stimulation and
normalized to the pre-100 Hz baseline. Significant effects of drug treat-
ment on LTP were determined within genotype using paired t tests.
Differences in LTP amplitude between WT and APP/PS1 KI mice were
compared using an unpaired t test.
Figure 1. Increase in IL-1 levels in the APP/PS1 KI mouse as a function of animal age, and
selective attenuation of IL-1 by extended administration ofMW-151 in a chronic intervention
paradigm. A, Neocortical tissue from WT (open circles) or APP/PS1 mice (closed circles) was
dissected from the brains of mice at different ages, and levels of IL-1mRNA and protein were
determined by qPCR or MSD ELISA, respectively. B, APP/PS1 mice were treated in a chronic
intervention paradigm with either saline vehicle (veh; open bars) or MW-151 (closed bars; 2.5
mg/kg i.p. three times weekly) beginning at early age (6 months old). At the end of the treat-
ment period, whenmicewere 11months old, neocortical tissuewas analyzed byMSD ELISA for
the levels of IL-1 and IL-10. MW-151 selectively attenuated the proinflammatory cytokine
IL-1, but not the anti-inflammatory cytokine IL-10. *p 0.05 compared to WT mice at 11
months old.
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Results
Validation of mechanism of action
endpoint in APPxPS1 mice
We reported previously (Hu et al., 2007)
that MW-151 is efficacious in a mouse
model of AD pathology that involves infu-
sion of human oligomeric A1–42 and rep-
resents disease in its early stages (Craft et al.,
2004a,b). However, the effect of the com-
pound in an AD model that exhibits more
severe amyloid plaque pathology and age-
dependentdiseaseprogressionhadnotbeen
examined. The first necessary step was to
choose an AD mouse model that exhibits
appropriate changes in the process that is
being targeted by our small molecule com-
pound. Since the mechanism of action of
MW-151is toattenuatecytokineoverproduc-
tion from activated glia, it was important to
select an animal model that exhibits in-
creases in glial activation and cytokine
production during the pathology progres-
sion. We selected the APPNLh/NLh 
PS1P264L/P264L mutantmousemodel (APP/
PS1) originally developed at Cephalon
(Flood et al., 2002), where gene expression in
this humanized APP/PS1 double knock-in
model is driven by endogenous promoters of
theAPPandPS-1genes.Thismodelpreserves
physiologically relevant APP expression levels
and demonstrates progressive AD pathology
without APP overproduction. Most impor-
tantly, we verified that this model shows an
age-dependent increase in levels of proin-
flammatory cytokines above that of WT
mice. As shown in Figure 1A, the levels of
IL-1mRNA and protein in the cortex in-
crease with age in both the WT and APP/PS1 KI mice, with the KI
mice showinga significantlyhigher level of IL-1 at 11months com-
pared to theWTmice.Thus, this is a relevant animalmodel inwhich
to test in vivo the efficacy of a cytokine response modulator.
Extended administration of MW-151 in chronic intervention
paradigm reduces proinflammatory cytokine levels
Based on the time course of the cytokine rise, we designed a
chronic dosing, prevention study paradigm where MW-151 (2.5
mg/kg i.p.) or saline vehicle was administered three times per
week (Monday, Wednesday, Friday) beginning at 6 months
(when cytokine levels are just beginning to increase) and ending
at 11 months (when cytokine overproduction is easily apparent).
Themice tolerated well the extended administration ofMW-151,
exhibiting no significant differences in survival or weight. As
shown in Figure 1B, APP/PS1 KI mice administered MW-151
showed lower levels of brain IL-1 compared to vehicle-treated
mice, but no decrease in the anti-inflammatory cytokine IL-10.
These data confirm that MW-151 exhibits its mechanism of ac-
tion, i.e., selective attenuation of brain proinflammatory cytokine
levels, in this animal model.
Chronic MW-151 administration attenuates microglial and
astrocyte activation
Theeffect ofMW-151 treatmentonglial activationwas examinedby
immunohistochemistry (IHC) using anti-IBA1 antibody to label
microglia and anti-GFAP antibody to label astrocytes. Immuno-
stained sections were scanned and converted into a high-resolution
digital image using the Aperio ScanScope digital slide scanner and
thepositive pixels algorithmor thenuclear algorithmtoquantify the
immunohistochemical staining. The Aperio ScanScope enables
high-resolution image recognition and rigorous digital pathological
quantitation. Figure 2A shows a representative field of IBA1-stained
microglia in the cortex and digital images of the algorithms used to
calculatemicroglial activation characteristics.MW-151 treatment of
APP/PS1 KImice reduced themicroglial activation when data were
expressed as either the number of positive pixels (Fig. 2B) or the
number of stained cells/mm2 (Fig. 2C).
In addition to effects onmicroglia activation,MW-151 adminis-
tration also attenuated astrocyte activation. Figure 3A illustrates the
GFAP-labeled hemi-brain sections.MW-151 treatment reduced the
astrocyte activation in cortex (Fig. 3B) and hippocampus (data not
shown), as quantified from the IHC. Interestingly,MW-151 had no
effect on GFAP mRNA levels (Fig. 3C). MW-151 treatment did,
however, reduce the mRNA levels of two other astrocyte markers.
Therewas a significant decrease in S100BmRNAanda trend toward
a decrease in vimentin mRNA (Fig. 3C).
Chronic MW-151 administration prevents synaptic
protein loss
The ability of chronic administration of MW-151 to lead to ben-
eficial neuronal changes was tested by measuring the levels of a
Figure 2. Chronic MW-151 administration attenuates microglial activation. A, Representative images of IBA1-stained micro-
glia in cortex of 11-month old APP/PS1mouse, demonstrating the positive pixel and nuclear algorithms used for quantification of
the staining. A computer-generatedmarkup of the algorithm is created by the ScanScope software, which validates the specificity
of the method. In the positive pixel algorithm, the microglia shown in shades of gray (indicating intensity of positive staining) is
segregated from the background shown as black. Themarkup in the nuclear algorithm shows the reliable detection and quantifi-
cation of individual cells (shownby the blackmarkup).B, C, TheAPP/PS1mice treatedwith vehicle (veh; gray bars) show increased
microglial staining compared to WT mice treated with vehicle (white bars). MW-151 treatment of the APP/PS1 mice (black bars)
reduced the microglial activation as assessed by either the stained area (B) or the number of stained microglia (C). *p 0.05
compared to vehicle-treated APP/PS1 mice. **p 0.01 compared to vehicle-treated APP/PS1 mice.
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panel of synaptic protein markers by Western blot analysis. The
APP/PS1 KI model exhibits synaptic dysfunction as seen by a
reduction in the levels of synaptic proteins compared toWTmice
(Fig. 4). MW-151 treatment of APP/PS1 KI mice prevented the
loss of the synaptic proteins PSD95 (Fig. 4A), synaptophysin
(Fig. 4B), syntaxin (Fig. 4C), and SNAP25 (Fig. 4D).
Selectivity of MW-151
In the AD brain, microglia exhibit a complex and heterogeneous
set of responses in attempts to restore homeostasis. Although our
understanding of the consequences of particular microglia re-
sponses to the neurodegenerative process in AD is limited, the
classical inflammatory activation state (termed M1) can lead to
overproduction of proinflammatory cytokines and subsequent
neuronal damage, while an alternative activation state (termed
M2) may be involved in attempts to prevent further damage or
promote tissue repair. To test the selectivity ofMW-151 action in
terms of its effects on selected microglia and neuron responses,
we measured a panel of markers by quantitative PCR (qPCR) in
the cortex from the vehicle-treated orMW-151-treated APP/PS1
Figure 3. Chronic MW-151 administration attenuates astrocyte activation. A, Representative images of GFAP-stained sections. B, The APP/PS1 mice treated with vehicle (veh; gray bars) show
increased astrocyte staining in cortex compared to WT mice treated with vehicle (white bars). MW-151 treatment of the APP/PS1 mice (black bars) reduced the astrocyte activation. C, MW-151
treatment had no effect on GFAP mRNA levels but did reduce mRNA levels of two other astrocyte markers, S100B and vimentin. **p 0.01 compared to vehicle-treated APP/PS1 mice.
Figure 4. Chronic MW-151 administration prevents synaptic loss. Neocortex tissue was an-
alyzed for the levels of synaptic proteins by Western blots. Compared to WT mice treated with
vehicle (veh;whitebars), theAPP/PS1mice treatedwith vehicle (graybars) showreduced levels
of the synaptic proteins PSD95 (A), synaptophysin (B), syntaxin (C), and SNAP25 (D). MW-151
treatment of the APP/PS1 mice protected against this loss of synaptic protein levels, restoring
the levels back toward WT values. *p 0.05 compared to vehicle-treated APP/PS1 mice.
Table 1. Selective effects of MW-151 on inflammation-related gene
expressionmarkers
 20% p 0.05 (*) Vehicle MW-151 Gene/TaqMan assay ID
IBA1 2 * 100 9 75 4 Aif1/Mm00479862_g1
CD45 100 8 88 10 Ptprc/Mm01293575_m1
CD68 2 * 100 9 74 2 Cd68/Mm00839636_g1
TLR2 100 13 118 17 Tlr2/Mm00442346_m1
TLR4 1 100 15 150 34 Tlr4/Mm00445273_m1
NOS2 100 15 113 18 Nos2/Mm00440502_m1
TNF 2 100 12 62 18 Tnf/Mm00443258_m1
TGF 2 * 100 7 75 3 Tgfb1/Mm00441726_m1
IGF1 2 100 28 76 17 Igf1/Mm00439561_m1
CD200 1 * 100 9 218 57 Cd200/Mm00487740_m1
Fractalkine 1 * 100 9 134 6 Cx3cl1/Mm00436454_m1
HMGB1 2 * 100 9 70 3 Hmgb1/Mm00849805_gH
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KI mice. The endpoints tested represent microglia markers, toll-
like receptors, M1 and M2 endpoints, neuroimmune regulatory
molecules, and a damage-associated molecular pattern (DAMP)
molecule. Table 1 shows that MW-151 modulates some end-
points but not others. For example, TNF is reduced butNOS2 is
not, even though both are considered M1 inflammatory mole-
cules. Similarly, one of the M2 markers is changed (TGF), but
not the other (IGF1). Other M2 markers in the qPCR array (fizz,
Arg1, BDNF) could not be measured accurately because they
were at very low to undetected levels in the assay. These results
with M2 markers are consistent with our previous observations
(data not shown) that in the absence of external stressor stimuli,
this APP/PS1 KI mouse model does not express many of the
standard M2 markers to an appreciable degree. Other microglia
markers also showed selective responses in that IBA1 and CD68
are reduced but CD45 is not. The neuroimmune regulatory mol-
ecules CD200 and fractalkine are increased, and the DAMP
HMGB1 is decreased by MW-151 treatment. Although the func-
tional significance of changes in these specific responses was not
explored as part of this study, these data confirm that MW-151 is
selective in its action and not a pan-suppressor of microglia and
neuron responses.
Short-termMW-151 treatment in acute
intervention paradigm
To test whether MW-151 is efficacious in older mice where dis-
ease pathology is already present, we administered MW-151 (2.5
mg/kg i.p.) or saline vehicle to 11-month-old mice once daily for
1 week. As shown in Figure 5A, short-term administration of
MW-151 in the acute intervention treatment paradigm attenu-
ated IL-1 production without significant reductions in IL-10,
and had no effect on microglial (IBA1) or astrocyte (GFAP) acti-
vation. Analysis of synaptic protein levels (Fig. 5B) showed that
MW-151 significantly protected the brain against loss of PSD95
and synaptophysin but was less effective against loss of syntaxin
and SNAP25.
No effects of MW-151 on amyloid plaque load or A40
or A42
We examined the effect of MW-151 treatment on amyloid
plaque burden in both the chronic and acute dosing para-
digms by staining brain sections with a polyclonal anti-A
N-terminal antibody. This antibody reacts with both A40
and A42 and is specific for human A. As shown in Figure
6A, the 11-month-old APP/PS1 mice exhibit abundant num-
bers of amyloid plaques at this age, similar to previous reports
using this model (Flood et al., 2002; Anantharaman et al.,
2006; Murphy et al., 2007). Analysis of amyloid plaque stain-
ing in the cortex demonstrates that MW-151 treatment in
either the chronic intervention paradigm (Fig. 6B) or the
acute intervention paradigm (Fig. 6C) had no significant effect
on amyloid plaque burden. There was also no effect of MW-
151 treatment on amyloid plaque load in the hippocampus
(data not shown). The lack of effect was seen when the data
were expressed either as percentage of the area stained with
anti-A antibody or as number of plaques per mm2. In addi-
tion, MW-151 treatment had no effect on the size of the amy-
loid plaques detected. To determine whether there was any
effect of MW-151 treatment on the levels of A, we prepared
PBS soluble, detergent soluble, and FA soluble fractions of
cortex and measured the levels of A40 and A42 by quanti-
tative A ELISA. No appreciable A was detected in the deter-
gent soluble fraction (data not shown). The amount of A40
or A42 in either the PBS soluble or FA soluble fractions was
Figure 5. Effects of short-termMW-151 treatment in acute intervention paradigm. Eleven-month-old mice were treated with either saline vehicle (veh; white bars, WT; gray bars, APP/PS1) or
with 2.5 mg/kg/d MW-151 i.p. (black bars, APP/PS) once daily for 1 week. Neocortex tissue was harvested and endpoints were measured. A, Short-term MW-151 treatment reduced the levels of
IL-1, but not IL-10, and hadno effect onmicroglial (IBA1) or astrocyte (GFAP) activation.B,MW-151 treatment prevented the loss of PSD95 and synaptophysin, but the protection against syntaxin
and SNAP25 loss did not reach significance. *p 0.05 compared to vehicle-treated APP/PS1 mice.
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not significantly different in the APP/PS1 KI mice treated with
vehicle or MW-151 in either the chronic (Fig. 6B) or acute
(Fig. 6C) intervention paradigm. These data are consistent
with the lack of effect on amyloid plaque burden and show that
A pathology overall was not significantly changed by MW-
151 treatment.
MW-151 treatment rescues
impairments in LTP
LTP is a widely studied experimentalmodel
of synaptic plasticity implicated in learning
and memory (Bliss and Collingridge, 1993;
Malenka and Nicoll, 1999). Because of the
well established link between elevated pro-
inflammatory cytokine levels and impair-
ments in LTP, along with observations that
anti-cytokine strategies rescue LTP deficits
(Rowan et al., 2007; Lynch, 2010; Yirmiya
and Goshen, 2011), we investigated the ef-
fect of MW-151 on synaptic function and
plasticity by LTP measurements. Coronal
brain slices from12-month-oldAPP/PS1KI
micewere prepared and incubated for1.5
h in oxygenatedACSF-containing saline ve-
hicle or 30MMW-151. Electrically evoked
EPSPs were obtained in hippocampal CA1
stratum radiatum, and LTP was induced
(Fig. 7A) using 100 Hz stimulus trains as
described previously (Mathis et al., 2011;
Norris and Scheff, 2009). Similar to previ-
ous findings with other APP/PS1 mouse
models (e.g., Trinchese et al., 2004), slices
from vehicle-treated APP/PS1 mice exhib-
ited significantly reduced LTP compared to
slices from age-matched WT controls (n	
5) (Fig. 7B,C). In contrast, LTP in MW-
151-treated slices from the APP/PS1 group
was similar in magnitude to the WT group
and significantly greater than that shown by
vehicle-treated APP/PS1 mice (p  0.05).
No genotype or drug treatment effects were
observed for other synaptic function mark-
ers, including basal synaptic strength (Fig.
7D) and paired-pulse facilitation (data not
shown). The results suggest that MW-151
treatment selectively enhances synaptic
plasticity mechanisms in APP/PS1 KImice.
Discussion
Wereport here several findingswith impor-
tant implications for future glia-targeted
AD therapeutic strategies. First, we show in
anAPP/PS1KImousemodel of ADpathol-
ogy that pharmacological intervention with
a selective, small molecule inhibitor of glial
proinflammatory cytokine overproduction
is efficacious at attenuating microglial and
astrocyte activation and proinflammatory
cytokine levels, which prevents loss of syn-
aptic proteins and impairments in synaptic
plasticity (LTP). Second, there were no ad-
verse effects observed with extended treat-
ment of aging mice with a therapy that
targets excessive proinflammatory cytokine
production. Third, the beneficial effects of
MW-151 occurred in the absence of a detectable change in amyloid
plaque load or in levels of soluble or aggregated forms of A40 or
A42measured in PBS soluble and FA soluble neocortical fractions.
Fourth, although MW-151 is effective when administration is
started at either early or later stages of diseasepathologyprogression,
Figure 6. No effect ofMW-151 treatment onA pathology.A, Representative images of A-stained hemi-brain sections.B, C,
In either the chronic interventionparadigm(B) or theacute interventionparadigm(C),MW-151 treatmentofAPP/PS1micedidnot
reduce theamyloidplaque loadwhenmeasuredasapercentageof thearea stainedor as thenumberofplaquesperunit area. There
were also no differences in the number of small (20–300), medium (301–1000), or large (1001-
) amyloid plaques detected.
MW-151 treatment of APP/PS1mice also had no significant effect on the levels of soluble or aggregated forms of A, asmeasured
by levels of A40 or A42 in PBS-soluble and FA-soluble fractions. veh, Vehicle.
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the compound is more effective in a preventative mode where ad-
ministration is initiated before full later stage pathology is emerging.
Overall, our results show that selective inhibition of the increasing
glia proinflammatory cytokine response in early time windows of
disease progression is beneficial at maintaining synaptic function,
suggesting the importance of therapeutic time window consider-
ations in future design of efficacy studies of neuroinflammation-
targeted drugs.
The observation thatMW-151 wasmore efficacious when ad-
ministered in a preventative paradigm before onset of overt pa-
thology implies that drugs that target neuroinflammationmay be
most beneficial when used early in the course of disease patho-
genesis. This is consistent with many studies demonstrating that
glial activation and neuroinflammation are early events in AD
pathogenesis (e.g., see Cagnin et al., 2001; Mrak and Griffin,
2005; Griffin and Barger, 2010; Carter et al., 2012), recent
genome-wide association study data showing that many of the
genes associatedwith increasedAD risk are inflammation-related
(Sleegers et al., 2010; Guerreiro et al., 2012), and epidemiological
and population-based clinical studies that suggest an association
between early use of nonsteroidal anti-inflammatory drugs
(NSAIDs) and reduced risk of developing AD (McGeer et al.,
1996; in’t Veld et al., 2001; Zandi and Breitner, 2001).
In addition, analysis of data (Breitner et al., 2011; Leoutsakos
et al., 2012) from the randomized clinical trial ADAPT (Alzhei-
mer’s Disease Anti-inflammatory Prevention Trial) suggest that
the treatment effects of NSAIDs differ depending on the stage of
disease, with potential beneficial effects in asymptomatic individ-
uals with little or no cognitive decline at the time of drug use, but
harmful effects in later stages of AD pathogenesis. Although
MW-151 is not an NSAID, the results reported here are consis-
tent with the idea that suppression of CNS inflammation is likely
to be effective as a prevention strategy before the self-pro-
pagating, proinflammatory cytokine cycle is too far advanced
during disease progression. However, MW-151 was also able to
block cytokine production and prevent the decrease in some syn-
aptic proteins even when administered at a later stage of pathol-
ogy progression (to 11-month old mice for only a week). These
initial observations will need to be followed up with more de-
tailed studies on the therapeutic window, but they suggest that
future anti-inflammatory strategies aimed at selective fine tuning
of neuroinflammation might be useful not only to prevent or
delay onset of AD, but potentially as part of therapeutic strategies
to treat existing disease, which would involve co-therapy with
other drugs.
MW-151 was discovered using a functional in vivo screen
(Ralay Ranaivo et al., 2006;Wing et al., 2006; Hu et al., 2007; Van
Eldik et al., 2007) that employed an animal model of injury in-
duced by toxic aggregates of human A1–42. That model lacked
an age-dependent progressive pathology and did not have an
amyloid plaque-rich environment. The APP/PS1 KI model used
here exhibits progressive amyloid plaque deposition, beginning
at around 9 months of age and increasing with age (Flood et al.,
2002; Anantharaman et al., 2006; Murphy et al., 2007). This
model also exhibits progressive pathological alterations in bidi-
rectional synaptic plasticity, cognitive measures, synaptosomal
membrane lipids, and oxidative stress markers as a function of
animal development and maturation (Anantharaman et al.,
2006; Chang et al., 2006; Bruce-Keller et al., 2011). We have
shown here that the APP/PS1 KI model also demonstrates an
early and progressive increase in brain proinflammatory cytokine
levels, and that dampening of the proinflammatory cytokine pro-
duction and the associated glial activation is beneficial to synaptic
function. In this regard, it is interesting to note that these bene-
ficial effects of MW-151 occurred in the absence of a detectable
effect on amyloid plaque load or a change in PBS soluble or FA
soluble A40/42 levels, demonstrating that MW-151 treatment
does not shift the levels of soluble toxic A oligomers or insoluble
fibrils.
There is inconsistency in the literature with respect to the
effect of blocking cytokine signaling on A pathology. Some
studies have reported that interference with cytokine signaling by
anti-inflammatory drug treatment or genetic deletion strategies
results in reduced amyloid plaque load (Lim et al., 2000; Jantzen
et al., 2002; Yan et al., 2003; Morihara et al., 2005; He et al., 2007;
Yamamoto et al., 2007). However, other studies have shown that
Figure 7. MW-151 increases LTP in the hippocampus of 12-month-old APP/PS1 mice. A,
Representative CA3-CA1 synaptic responses from vehicle (veh)-treated and 30 M MW-151-
treated hippocampal slices fromAPP/PS1mice, collected immediately before (dashed line) and
60 min after (solid line) LTP induction. B, Time plot of EPSP slope measures taken before and
after 100 Hz stimulation in slices fromWT mice (white circles) and APP/PS1 mice treated with
(black circles) orwithout (gray circles)MW-151. C, Bar graph shows LTP levels across treatment
conditions. Number symbol (#) indicates a significant decrease ( p 0.05) in LTP in vehicle-
treated slices from APP/PS1 mice compared to vehicle-treated slices from WT mice. Asterisk
indicates a significant increase ( p 0.05) in LTP inMW-151-treated slices from APP/PS1mice
relative to the APP/PS1 vehicle group. D, EPSP slope measures plotted against FV measures in
each treatment condition. No effects of genotype or MW-151 treatment on synaptic strength
were observed.
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cytokine-suppressing strategies can reduce brain inflammatory
responses and attenuate markers of neuronal pathology with lit-
tle or no effect on amyloid plaque pathology (Ralay Ranaivo et al.,
2006; Kitazawa et al., 2011). Therefore, it is possible that an im-
pact on amyloid plaques might be due to the model being used,
the pharmacodynamic profile of the particular drug, the thera-
peutic time window of treatment and pathology development, or
any combination of these variables. Our results with MW-151
pharmacodynamics in this particular model clearly demonstrate
that synaptic and glia endpoints, related respectively to efficacy
and in vivo mechanism of drug action, can be modulated inde-
pendently of effects on A. The linkage to tau pathology or its
interface with A pathology (Zilka et al., 2012) cannot be ad-
dressed in this model because the APP/PS1 KI mouse lacks
AD-relevant tau pathology. Thus, the interplay between glia pro-
inflammatory cytokine-linked neuropathologies and AD-
relevant tau neurofibrillary pathology remains to be addressed in
future studies.
The linkage between changes in proinflammatory cytokine levels
and neurologic outcomes, revealed by the improvement in synaptic
endpoints (synapticprotein levels andLTP)after attenuationofpro-
inflammatory cytokine levels by MW-151 treatment, is consistent
with previous reports of MW-151 efficacy in other rodent CNS in-
jury models, including oligomeric A-induced injury (Hu et al.,
2007), kainic acid-induced seizures (Somera-Molina et al., 2007, 2009),
Traumatic Brain Injury models (Lloyd et al., 2008; Chrzaszcz et al.,
2010),andtheExperimentalAutoimmuneEncephalomyelitismodelof
multiple sclerosis (Karpus et al., 2008). These previous studies docu-
mented thatMW-151efficacyat reducing injury-inducedupregulation
of proinflammatory cytokine levels was associated with a reduction in
long-termneuronal injuryandattenuationofhippocampal-dependent
cognitivedeficits.Our findingsarealsoconsistentwithreports thathave
linked other anti-neuroinflammatory interventions with changes in
synaptic plasticity. For example, pharmacological interventions and/or
genetic manipulations that suppress proinflammatory cyto-
kine signaling normalize synaptic function in primary neural
cultures (Sama et al., 2008) and ameliorate LTP deficits asso-
ciated with aging (Griffin et al., 2006; Cowley et al., 2012) and
A (Rowan et al., 2007; Kotilinek et al., 2008; Yirmiya et al.,
2011).
Overall, the data reported here add to the growing body of
evidence that has identified dysregulated glial activation and
proinflammatory cytokine overproduction as a common early
pathophysiologic mechanism and potential therapeutic target in
diverse neurodegenerative disorders. In addition, the results ex-
tend this state of knowledge to therapeutic intervention possibil-
ities, especially the importance of therapeutic time window
considerations in the design of intervention strategies.
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